Lawsuits against EpiPen maker Mylan moving forward

Lawsuits against EpiPen maker Mylan moving forwardEmbedShareA competitor to EpiPen is set to be released in 2017, but the price is still unclear. USA TODAYEmbedShareCongress held a hearing on the EpiPen price hikes Wednesday, Sept. 21. Here are five takeaways from the hearing. USA TODAYEmbedShare"You've been in these hallways to ask us to make people buy your stuff," U.S. Rep. Mick Mulvaney said. Video provided by Newsy NewslookEmbedShareThe CEO of Mylan defended the price of the company's Epipen product during a House Oversight and Government Reform Committee hearing Wednesday. (Sept. 21) EmbedShareGayle Manchin, mother of Mylan CEO Heather Bresch, helped boost sales of the EpiPen in her position as president of the National Association of State Boards of Education. USA TODAYEmbedShareMylan is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. A pharmacist holds a package of EpiPen epinephrine auto-injector, a Mylan product.(Photo: Rich Pedroncelli, AP)CINCINNATI — The maker of the EpiPen that came under fire for boosting the price of the lifesaving allergy medication sky high may have quieted the controversy by introducing a generic version, but now faces a raft of lawsuits.Several proposed class-action cases against drugmaker Mylan involving EpiPens have been brought in federal courts around the country, including two in Kansas and two in northern California.One was filed by a Cincinnati attorney against Mylan after it raised the price of its EpiPen injectors by 500% since 2009.Since the lawsuit was filed Sept. 6, the case has been transferred to federal court, and there are now about 100 people who have signed on to the proposed class-action case.The attorney who filed the lawsuit, Carl Lewis, said more people are seeking to join. He is waiting for the judge to formally certify it as a class-action.“We are waiting for the court’s certification of the case as a class,” Lewis said in an email.At the time, only one other lawsuit surrounding EpiPens, filed in federal court in Michigan, had been publicized.Mylan itself has faced intense scrutiny, with CEO Heather Bresch being called to testify in September before a U.S. House committee. During that testimony, Bresch defended the pricing of EpiPens.She also announced that the company would offer a “generic version” of its own product that would cost $300, about half of the wholesale price.A month later, in October, Mylan announced that it had agreed to terms of a $465 million settlement with the U.S. Department of Justice and other government agencies. The settlement was intended to resolve claims that Mylan wrongly classified EpiPen devices as generic drugs under Medicaid.The classification allowed Mylan to pay a lower rebate to states “and reap huge profits at the expense of taxpayers,” according to a letter sent by U.S. Sen Richard Blumenthal to the justice department.In that same letter, Blumenthal called on the justice department to reject the settlement.The Senate Judiciary Committee scheduled its own hearing last month but canceled it when officials said representatives from the justice department, the Centers for Medicare and Medicaid Services and Mylan all refused to attend.The lawsuit filed by Lewis describes the plight of lead plaintiff Linda Bates, a Cincinnati resident who saw her cost for EpiPens go from about $50 last year to $600 this year.Bates’ teenage son has a peanut allergy that has required him to carry an EpiPen since he was 5 years old. The medication in the device, epinephrine, reverses an allergic reaction known as anaphylaxis. The medication lasts about a year, and every year Bates has to buy a new one. Since 2011, after a federal agency’s recommendation, the devices have been sold in the U.S. with only two injectors in each pack.In Canada, an EpiPen sells for just over $100 per injector, and it is possible to buy a single injector.“The only country in the world where Mylan requires a customer to purchase a Two-Pak of the EpiPen is the United States,” according to a lawsuit filed by The Lanier Law Firm and Sharp Law in federal court in Kansas. The lawsuit says there is no medical reason to require that people buy two.“This discrepancy proves that Mylan is motivated by profits and greed, not medicine or the welfare of its customers,” the lawsuit says.The lawsuit also alleges Mylan has a monopoly. Competitors, it says, have been unsuccessful in lobbying the Food and Drug Administration to approve another auto-injector “that can reliably deliver the right amount of epinephrine.”Last year, Mylan said its EpiPen was “the number-one dispensed epinephrine auto-injector.” Globally, EpiPens accounted for $1 billion in annual net sales in 2015.A spokeswoman for Mylan declined to comment about the EpiPen lawsuits.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Lawsuits against EpiPen maker Mylan moving forward

Lawsuits against EpiPen maker Mylan moving forwardEmbedShareA competitor to EpiPen is set to be released in 2017, but the price is still unclear. USA TODAYEmbedShareCongress held a hearing on the EpiPen price hikes Wednesday, Sept. 21. Here are five takeaways from the hearing. USA TODAYEmbedShare"You've been in these hallways to ask us to make people buy your stuff," U.S. Rep. Mick Mulvaney said. Video provided by Newsy NewslookEmbedShareThe CEO of Mylan defended the price of the company's Epipen product during a House Oversight and Government Reform Committee hearing Wednesday. (Sept. 21) EmbedShareGayle Manchin, mother of Mylan CEO Heather Bresch, helped boost sales of the EpiPen in her position as president of the National Association of State Boards of Education. USA TODAYEmbedShareMylan is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. A pharmacist holds a package of EpiPen epinephrine auto-injector, a Mylan product.(Photo: Rich Pedroncelli, AP)CINCINNATI — The maker of the EpiPen that came under fire for boosting the price of the lifesaving allergy medication sky high may have quieted the controversy by introducing a generic version, but now faces a raft of lawsuits.Several proposed class-action cases against drugmaker Mylan involving EpiPens have been brought in federal courts around the country, including two in Kansas and two in northern California.One was filed by a Cincinnati attorney against Mylan after it raised the price of its EpiPen injectors by 500% since 2009.Since the lawsuit was filed Sept. 6, the case has been transferred to federal court, and there are now about 100 people who have signed on to the proposed class-action case.The attorney who filed the lawsuit, Carl Lewis, said more people are seeking to join. He is waiting for the judge to formally certify it as a class-action.“We are waiting for the court’s certification of the case as a class,” Lewis said in an email.At the time, only one other lawsuit surrounding EpiPens, filed in federal court in Michigan, had been publicized.Mylan itself has faced intense scrutiny, with CEO Heather Bresch being called to testify in September before a U.S. House committee. During that testimony, Bresch defended the pricing of EpiPens.She also announced that the company would offer a “generic version” of its own product that would cost $300, about half of the wholesale price.A month later, in October, Mylan announced that it had agreed to terms of a $465 million settlement with the U.S. Department of Justice and other government agencies. The settlement was intended to resolve claims that Mylan wrongly classified EpiPen devices as generic drugs under Medicaid.The classification allowed Mylan to pay a lower rebate to states “and reap huge profits at the expense of taxpayers,” according to a letter sent by U.S. Sen Richard Blumenthal to the justice department.In that same letter, Blumenthal called on the justice department to reject the settlement.The Senate Judiciary Committee scheduled its own hearing last month but canceled it when officials said representatives from the justice department, the Centers for Medicare and Medicaid Services and Mylan all refused to attend.The lawsuit filed by Lewis describes the plight of lead plaintiff Linda Bates, a Cincinnati resident who saw her cost for EpiPens go from about $50 last year to $600 this year.Bates’ teenage son has a peanut allergy that has required him to carry an EpiPen since he was 5 years old. The medication in the device, epinephrine, reverses an allergic reaction known as anaphylaxis. The medication lasts about a year, and every year Bates has to buy a new one. Since 2011, after a federal agency’s recommendation, the devices have been sold in the U.S. with only two injectors in each pack.In Canada, an EpiPen sells for just over $100 per injector, and it is possible to buy a single injector.“The only country in the world where Mylan requires a customer to purchase a Two-Pak of the EpiPen is the United States,” according to a lawsuit filed by The Lanier Law Firm and Sharp Law in federal court in Kansas. The lawsuit says there is no medical reason to require that people buy two.“This discrepancy proves that Mylan is motivated by profits and greed, not medicine or the welfare of its customers,” the lawsuit says.The lawsuit also alleges Mylan has a monopoly. Competitors, it says, have been unsuccessful in lobbying the Food and Drug Administration to approve another auto-injector “that can reliably deliver the right amount of epinephrine.”Last year, Mylan said its EpiPen was “the number-one dispensed epinephrine auto-injector.” Globally, EpiPens accounted for $1 billion in annual net sales in 2015.A spokeswoman for Mylan declined to comment about the EpiPen lawsuits.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>